摘要
目的观察健择(吉西他滨)联合顺铂治疗晚期非小细胞肺癌3周和4周方案的疗效和不良反应。方法入选经病理和细胞学证实的晚期非小细胞肺癌(NSCLC)患者,既往未进行化疗和放疗,临床上有可测量病灶(根据WHO标准),ECOG评分为0分～2分,肝肾功能基本正常。均给予健择和顺铂的联合化疗方案。按照WHO的标准评价疗效和不良反应,并随访生存期。结果共入组33例患者,其中29例可评价疗效,其中14例部分缓解(48.3%)、8例病情稳定(27.6%)和7例疾病进展(24.1%)。中位生存期为9.1月,范围为2.7月～19.1月。主要的不良反应为血液学毒性,表现为白细胞下降、中性粒细胞下降、血小板下降和血红蛋白下降,其次为消化道症状。结论健择是有效的抗肿瘤药物,与顺铂联合应用是晚期NSCLC的标准一线化疗方案之一,患者可很好耐受。
OBJECTIVE:To observe curative effect and adverse reactions of gemzar (gemcitabine) combined with cisplatin for the treatment of late NSCLC for 3 and 4 weeks. METHODS: The patients with late NSCLC verificated by pathology and cytology were chosen, who didn’t undertake chemotherapy and radiotherapy in the past. They were found to have clinically measurable focus (based on WHO standard ), ECOG sore ranged from 0 to 2 and heptic and renal function were basically normal. They were all given gemzar combined with cisplatin. Curative effect and adverse reactions were evaluated by WHO standard. Their survival time was followed up. RESULTS : 33 cases were elected into the study group. Of those, curative effect in 29 cases could be evaluated. 14 of 29 cases were PR(48.3%) ; 8 cases were SD(27.6%) and 7 cases were PD(24.1%). Neutral survival time was 9.1 months, ranging from 2.7 to 19.1 months. The main adverse reactions were hematologic toxicity. The manifestations were : WBC, neutrophile granulocyte, blood platelet and hemoglobin all decreased, then was digestive canal symptoms. CONCLUSION: Gemzar is an effective antitumor drug, which combines with cisplatin is one of the first-line chemotherapy project for late NSCLC. The patients can be well tolerant.
出处
《中国医院用药评价与分析》
2004年第6期361-363,共3页
Evaluation and Analysis of Drug-use in Hospitals of China
